Palatin Technologies, Inc. (PTN), a biopharmaceutical firm focused on melanocortin-based treatments, has priced a public offering totaling approximately $11.5 million.
The deal includes 76.7 million shares and accompanying Series F, G, and H warrants, all priced at $0.15 per unit. The offering attracted both new and existing healthcare-focused institutional investors, along with participation from Palatin's CEO, CFO, and board members, including its chairperson.
The Series F warrants are immediately exercisable at $0.30 per share and expire in five years. Series G warrants, exercisable at $0.15, expire after two years or upon the FDA Exercise Period deadline. Series H warrants, issued upon G warrant exercise, are priced at $0.225 and also expire in two years.
Closing is anticipated around May 8, 2025, pending standard conditions. Palatin may raise an additional $11.5 million if the Series G warrants are fully exercised, though this is not guaranteed. Net proceeds will primarily support general operations and the company's obesity drug development efforts.
PTN is currently trading at $0.0941 or 43.90$ lower on the NYSE American.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.